enVVeno Medical
NVNO
36 hedge funds and large institutions have $2.1M invested in enVVeno Medical in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0.04% more ownership
Funds ownership: 0.89% → 0.93% (+0.04%)
0% more funds holding
Funds holding: 36 → 36 (0)
61% less capital invested
Capital invested by funds: $5.4M → $2.1M (-$3.3M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$361K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$103K |
| 3 |
Two Sigma Investments
New York
|
+$88.6K |
| 4 |
Jane Street
New York
|
+$59.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$312K |
| 2 |
WIM
Westside Investment Management
Santa Monica,
California
|
-$66.7K |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$51.9K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$36.3K |
| 5 |
TS
Tamar Securities
Woodland Hills,
California
|
-$12.7K |
NVNO Hedge Fund Activity: Q4 2025 in Review
36 of the 8,230 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q4 2025, worth a combined $2.1M — down 61% from $5.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NVNO positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 10 trimmed.
The largest buyer was CM Management, adding an estimated $361K. The largest seller was Vanguard Group, cutting an estimated $312K.
- 36 institutional investors held enVVeno Medical (NVNO) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $2.1M of enVVeno Medical stock for Q4 2025, down 61% quarter-over-quarter.
- 4 funds opened new enVVeno Medical positions in Q4 2025 and 3 closed out, a net change of +1 holder.
- The largest enVVeno Medical buyer in Q4 2025 was CM Management, an estimated $361K added.
- The largest enVVeno Medical seller in Q4 2025 was Vanguard Group, an estimated $312K sold.
Based on aggregated 13F filings for Q4 2025.